超促排卵启动前3天拮抗剂预处理对拮抗剂方案体外受精-胚胎移植治疗结局的影响:一项随机对照试验

注册号:

Registration number:

ChiCTR1800019730 

最近更新日期:

Date of Last Refreshed on:

2023-06-25 22:29:01 

注册时间:

Date of Registration:

2018-11-26 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

超促排卵启动前3天拮抗剂预处理对拮抗剂方案体外受精-胚胎移植治疗结局的影响:一项随机对照试验

Public title:

Effect of three day antagonist pretreatment before superovulation initiation on outcome of in vitro fertilization-embryo transfer treatment with antagonist protocol: a randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

超促排卵启动前3天拮抗剂预处理对拮抗剂方案体外受精-胚胎移植治疗结局的影响:一项随机对照试验

Scientific title:

Effect of three day antagonist pretreatment before superovulation initiation on outcome of in vitro fertilization-embryo transfer treatment with antagonist protocol: a randomized controlled trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张译升 

研究负责人:

张译升 

Applicant:

Zhang Yisheng 

Study leader:

Zhang Yisheng 

申请注册联系人电话:

Applicant telephone:

+86 151 7717 2501

研究负责人电话:

Study leader's
telephone:

+86 151 7717 2501

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

175125941@qq.com

研究负责人电子邮件:

Study leader's E-mail:

175125941@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广西壮族自治区南宁市青秀区桃源路6号

研究负责人通讯地址:

广西壮族自治区南宁市青秀区桃源路6号

Applicant address:

6 Taoyuan Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region, China

Study leader's address:

6 Taoyuan Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region, China

申请注册联系人邮政编码:

Applicant postcode:

530021

研究负责人邮政编码:

Study leader's postcode:

530021

申请人所在单位:

广西壮族自治区人民医院

Applicant's institution:

The People's Hospital of Guangxi Zhuang Autonomous Region

研究负责人所在单位:

广西壮族自治区人民医院

Affiliation of the Leader:

The People's Hospital of Guangxi Zhuang Autonomous Region

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

科研-(院内青年基金)-2018-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

广西壮族自治区人民医院伦理委员会

Name of the ethic committee:

Ethics committee of people's hospital of guangxi zhuang autonomous region

伦理委员会批准日期:

Date of approved by ethic committee:

2018-10-12 00:00:00

伦理委员会联系人:

曾春,邱想英

Contact Name of the ethic committee:

Zeng Chun, Qiu Xiang-ying

伦理委员会联系地址:

广西壮族自治区南宁市青秀区桃源路6号

Contact Address of the ethic committee:

6 Taoyuan Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广西壮族自治区人民医院

Primary sponsor:

The People's Hospital of Guangxi Zhuang Autonomous Region

研究实施负责(组长)单位地址:

广西壮族自治区南宁市青秀区桃源路6号

Primary sponsor's address:

6 Taoyuan Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广西壮族自治区

市(区县):

南宁

Country:

China

Province:

Guangxi Zhuang Autonomous Region

City:

Nanning

单位(医院):

广西壮族自治区人民医院

具体地址:

广西壮族自治区南宁市青秀区桃源路6号

Institution
hospital:

the People's Hospital of Guangxi Zhuang Autonomous Region

Address:

6 Taoyuan Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region, China

经费或物资来源:

院内青年基金

Source(s) of funding:

Hospital youth fund

研究疾病:

不孕症  

Target disease:

infertility

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

在卵泡早期利用GnRH-ant预处理抑制FSH、LH及P提前升高,抑制卵泡提前募集,使得卵泡发育同步化,从而增加获卵数、胚胎数,同时探讨其是否影响临床妊娠率、持续妊娠率、流产率、活产率。  

Objectives of Study:

GnRH-ant pretreatment was used in the early stage of follicle to inhibit FSH, LH and P increase in advance, inhibit follicle recruitment in advance, and synchronize follicle development, thereby increasing the number of eggs and embryos, and at the same time to explore whether it affects clinical pregnancy rate, continuous pregnancy rate, abortion rate and live birth rate.

药物成份或治疗方案详述:

GnRH拮抗剂 (思泽凯) 

Description for medicine or protocol of treatment in detail:

GnRH antagonists 

纳入标准:

Inclusion criteria

排除标准:

1、月经紊乱,内分泌激素异常,如高泌乳素血症,甲状腺疾病。
2、子宫及卵巢手术史,
3、卵巢储备功能减退,FSH>12U/L或AFC<8或AMH<1.1ng/ml
4、子宫内膜病变(内膜息肉、宫腔粘连史等)、子宫畸形、子宫肌瘤(肌瘤大于3cm或与内膜关系密切)、子宫内膜异位症III-IV期、子宫腺肌症、输卵管积液等。
5、复发性流产史、反复种植失败史、染色体异常,BMI > 30 kg/m2。
6、男方严重少弱精子症或梗阻性无精子症。
7、不同意签署本研究的知情同意书。

Exclusion criteria:

1. Menstrual disorders, abnormal endocrine hormones, such as hyperprolactinemia, thyroid diseases;
2. History of uterine and ovarian surgery;
3. Ovarian reserve function decreased, FSH>12U/L or AFC<8 or AMH<1.1ng/ml;
4. Endometriosis (endometrial polyps, uterine adhesion history, etc.), uterine malformation, uterine fibroids (fibroids larger than 3cm or closely related to endometriosis), endometriosis stage iii-iv, adenomyosis, tubal effusion, etc.;
5. History of recurrent abortion, repeated implantation failure, chromosomal abnormality, BMI > 30kg /m2;
6. Male severe oligospermia or obstructive azoospermia;
7. Patients with known congenital adrenal hyperplasia.

研究实施时间:

Study execute time:

From 2018-12-01 00:00:00 To 2019-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2018-12-01 00:00:00 To 2019-12-31 00:00:00

干预措施:

Interventions:

组别:

实验组

样本量:

68

Group:

experimental group

Sample size:

干预措施:

经期第2-4天使用GnRH-ant预处理

干预措施代码:

Intervention:

GnRH-ant pretreatment was used on the 2nd to 4th day of menstruation

Intervention code:

组别:

对照组

样本量:

68

Group:

control group

Sample size:

干预措施:

经期第2-4天不用GnRH-ant预处理

干预措施代码:

Intervention:

No GnRH-ant pretreatment was used on the 2nd to 4th day of menstruation

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广西壮族自治区 

市(区县):

南宁市 

Country:

China

Province:

Guangxi Zhuang Autonomous Region

City:

Nanning

单位(医院):

广西壮族自治区人民医院 

单位级别:

三级甲等 

Institution
hospital:

The People's Hospital of Guangxi Zhuang Autonomous Region

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

获卵数

指标类型:

主要指标

Outcome:

Oocyte number

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Gn量

指标类型:

次要指标

Outcome:

Gn dose

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Gn天数

指标类型:

次要指标

Outcome:

Gn days

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

成熟卵数

指标类型:

次要指标

Outcome:

Number of mature eggs

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

受精率

指标类型:

次要指标

Outcome:

Fertilization rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

优质胚胎数

指标类型:

次要指标

Outcome:

Good embryo number

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

种植率

指标类型:

次要指标

Outcome:

Implantation rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

临床妊娠率

指标类型:

次要指标

Outcome:

clinical pregnancy rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

继续妊娠率

指标类型:

次要指标

Outcome:

ongoing pregnancy rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

流产率

指标类型:

次要指标

Outcome:

rate of abortion

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

活产率

指标类型:

次要指标

Outcome:

live birth rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 39 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

采用SPSS统计软件产生随机数字,区组随机化的方法,区组长度=4。本研究为单中心、前瞻性、随机、平行对照研究,按照随机数字表法产生随机分配序列表。本试验不涉及盲法,受试者充分知情同意。

Randomization Procedure (please state who generates the random number sequence and by what method):

SPSS statistical software was used to generate random Numbers and block randomization method, and block length = 4.This study is a single-center, prospective, random and parallel control study, and the random distribution sequence table is generated according to the random number table method.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

本研究因为无盲法实施条件(无法获取与GnRH-ant剂型和外形一致的安慰剂),故不适合盲法设计,但仍作部分设盲,如对参与研究的医生、护士、胚胎室成员及激素检测人员等设盲。

Blinding:

This study is not suitable for the blind method design due to the non-blind implementation conditions (unable to obtain the placebo which is consistent with GnRH-ant dosage form and shape), but it is still partially blinded, such as the doctors, nurses, embryo room members and hormone detection personnel involved in the study.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

广西壮族自治区人民医院生殖中心

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Reproductive center of people's hospital of guangxi zhuang autonomous region

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据录入采用ART电子病历系统及纸质档案,输入EXCEL表格保存

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data input using ART electronic medical record system and paper files, input EXCEL form preservation

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2018-11-26 00:04:25